一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Zongertinib；Pembrolizumab；Atezolizumab；Durvalumab；Nivolumab，当前状态为招募中。登记地点显示中国北京、长春、长沙、成都等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Zongertinib；Pembrolizumab；Atezolizumab；Durvalumab；Nivolumab · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- China-Japan Friendship Hospital · 北京
- Beijing Chest Hospital, Capital Medical University · 北京
- The First Hospital of Jilin University · 长春
- Xiangya Hospital, Central South University · 长沙
- Hunan Province Tumor Hospital · 长沙
- Sichuan Cancer Hospital · 成都
- West China Hospital, Sichuan University · 成都
- The First Affiliated Hospital,Sun Yat-sen University · 广州
- The First Affiliated Hospital, Zhejiang University · 杭州
- Zhejiang Cancer Hospital · 杭州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Shandong Cancer Hospital · 济南
- Yunnan Provincial Tumor Hospital · 昆明
- Linyi Cancer Hospital · 临沂
- The First Affiliated Hospital of Nanchang University · 南昌
- Nanjing Drum Tower Hospital · 南京
- Ningbo Second Hospital · 宁波
- Shanghai East Hospital · 上海
- Shanghai Pulmonary Hospital · 上海
- Hebei Provincial Tumor Hospital · 石家庄
- The First Affiliated Hospital of Soochow University · 苏州
- Taizhou Hospital of Zhejiang Province · 台州
- Tianjin Cancer Hospital · 天津
- Tianjin Medical University General Hospital · 天津
- Union Hospital Tongji Medical College Huazhong University of Science and Technology · 武汉
- The Affiliated Hospital of Xuzhou Medical College · 徐州
- Northern Jiangsu People's Hospital · 扬州
- Henan Cancer Hospital · 郑州
公开的入选条件
- Inclusion criteria:
- 1. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
- 2. Patients must be ≥18 years old or over the legal age of consent in their country
- 3. Male or female patients. Women of childbearing potential (WOCBP) must be ready and able to use dual highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A
- 4. HER2 mutation: Documented Tyrosine kinase domain (TKD) activating Human epidermal growth factor receptor 2 (HER2) mutations
- 5. Histology and tumor sample: Histologically confirmed diagnosis of primary NSCLC
- 6. An archival tumor tissue sample must be submitted to the central laboratory after inclusion of the patient to retrospectively confirm the HER2 status
- 7. Staging: Pretherapeutic classification not exceeding Stage IIIB
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07195695；登记信息更新于 2026-09-17。